Abstract
5-Methoxypsoralen (5-MOP) in combination with ultraviolet light exposure is used for the treatment of psoriasis. The effect of food on the pharmacokinetics of 5-MOP was evaluated in a randomized, crossover study in nine healthy subjects. Each subject received the tablets with a standardized breakfast or under fasting conditions. The food had a dramatic effect on the bioavailability of 5-MOP. Five of the subjects showed no measurable quantities (detection limit of the analytical technique 1 ng·ml-1) of 5-MOP when the drug was given under fasting conditions. However, plasma peak concentration within the range 37–144 ng·ml-1 (median 102 ng·ml-1) was measured when the drug was taken with food. The time for the plasma peak concentration was within the range 2.0–5.1 h (median 3.0 h) under non-fasting conditions. The elimination half-life was within the range 1.4–2.7 h (median 1.9 h). We conclude that it is imperative that 5-MOP tablets are administered together with food.
This is a preview of subscription content, log in via an institution to check access.
References
Moseley H, Ferguson J (1989) Photochemotherapy A reappraisal of its use in dermatology. Drugs 38: 822–837
Brickl R, Schmid J, Koss FW (1984) Clinical pharmacology of oral psoralen drugs. Photodermatol 1: 174–186
Hönigsmann H, Jaschke E, Gschnait F, Brenner W, Fritsch P, Wolff K (1979) 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis. Br J Dermatol 101: 369–378
Peyron JL, Meynadier J (1981) Comparison of PUVA-5MOP and PUVA-8MOP. Proc Int Psoralens 257–261
Tanew A, Ortel B, Rappersberger K, Hönigsmann H (1988) 5-Methoxypsoralen (Bergapten) for photochemotherapy. J Am Acad Dermatol 18: 333–338
Kalis B, Sayag S, Forlot P (1989) Photochemotherapy (PUVA) of psoriasis: a double-blind comparative study of 5- and 8-methoxypsoralen. In: Fitzpatrick TB, Forlot P, Pathak MA, Urbach F (eds) Psoralens: past, present and future of photochemoprotection and other biological activities. Libbey, Paris
George SA, Ferguson J (1992) Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute nonphototoxic adverse effects. Photodermatol Photoimmunol Photomed 9: 33–35
Swanbeck G, Ehrsson H, Ehrnebo M, Wallin I, Jonsson L (1979) Serum concentration and phototoxic effect of methoxalen in patients with psoriasis. Clin Pharmacol Ther 25: 478–480
Wagner G, Hofmann C, Busch U, Schmid J, Plewig G (1979) 8-MOP plasma levels in PUVA problem cases with psoriasis. Br J Dermatol 101: 285–292
Herfst MJ, De Wolff FA (1983) Intraindividual and interindividual variability in 8-methoxypsoralen kinetics and effect in psoriatic patients. Clin Pharmacol Ther 34: 117–124
Melander A, Lalka D, McLean A (1988) Influence of food on the presystemic metabolism of drugs. Pharmacol Ther 38: 253–267
Winstanley PA, Orme MLE (1989) The effects of food on drug bioavailability. Br J Clin Pharmacol 28: 621–628
Pfeifer S (1993) Einfluss von Nahrung auf die Pharmakokinetik von Arzneistoffen. Pharmazie 48: 3–16
Ehrsson H, Nilsson SO, Ehrnebo M, Wallin I, Wennersten G (1979) Effect of food on kinetics of 8-methoxalen. Clin Pharmacol Ther 25: 167–171
Roelandts R, Van Boven M, Deheyn T, Vander Stichele G, Degreef H, Daenens P (1981) Dietary influences on 8-MOP plasma levels in PUVA patients with psoriasis. Br J Dermatol 105: 569–572
Herfst MJ, De Wolff FA (1982) Influence of food on the kinetics of 8-methoxypsoralen in serum and suction blister fluid in psoriatic patients. Eur J Clin Pharmacol 23: 75–80
Melander A, Danielson K, Hanson A, Rudell B, Schersten B, Thulin T, W»hlin E (1977) Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther 22: 104–107
John BA, Chasseaud LF, Wood SG, Forlot P (1992) Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog. Xenobiotica 22: 1339–1351
Schmid J, Prox A, Zipp H, Koss FW (1980) The use of stable isotopes to prove the saturable first-pass effect of methoxalen. Biomed Mass Spectrom 7: 560–564
Schmid J, Prox A, Reuter A, Zipp H, Koss FW (1980) The metabolism of 8-methoxypsoralen in man. Eur J Drug Metab Pharmacokinet 5: 81–92
Stolk LML, Westerhof W, Cormane RH, Van Zwieten PA (1981) Serum and urine concentrations of 5-methoxypsoralen after oral administration. Br J Dermatol 105: 415–420
Stolk LML, Siddiqui AH, Westerhof W, Cormane RH (1985) Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen. Br J Dermatol 112: 469–473
Makki S, Quencez E, Humbert P, Taillard C, Agache P, Guinchard C (1989) 5-Methoxypsoralen pharmacokinetics in psoriatic patients. In: Fitzpatrick TB, Forlot P, Pathak MA, Urbach F (eds) Psoralens: past, present and future of photochemoprotection and other biological activities. Libbey, Paris
Oberle RL, Amidon GL (1987) The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 15: 529–544
Plusquellec Y, Campistron G, Staveris S, Barre J, Jung L, Tillement JP, Houin G (1987) A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 15: 225–239
Veng-Pedersen P, Miller R (1980) Pharmacokinetics of doxycycline reabsorption. J Pharm Sci 69: 204–207
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ehrsson, H., Wallin, I., Ros, A.M. et al. Food-induced increase in bioavailability of 5-methoxypsoralen. Eur J Clin Pharmacol 46, 375–377 (1994). https://doi.org/10.1007/BF00194409
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00194409